337 related articles for article (PubMed ID: 30628065)
1. Value of global metabolomics in association with diagnosis and clinicopathological factors of renal cell carcinoma.
Sato T; Kawasaki Y; Maekawa M; Takasaki S; Saigusa D; Ota H; Shimada S; Yamashita S; Mitsuzuka K; Yamaguchi H; Ito A; Kinoshita K; Koshiba S; Mano N; Arai Y
Int J Cancer; 2019 Jul; 145(2):484-493. PubMed ID: 30628065
[TBL] [Abstract][Full Text] [Related]
2. Accurate quantification of urinary metabolites for predictive models manifest clinicopathology of renal cell carcinoma.
Sato T; Kawasaki Y; Maekawa M; Takasaki S; Shimada S; Morozumi K; Sato M; Kawamorita N; Yamashita S; Mitsuzuka K; Mano N; Ito A
Cancer Sci; 2020 Jul; 111(7):2570-2578. PubMed ID: 32350988
[TBL] [Abstract][Full Text] [Related]
3. Prediction and diagnosis of renal cell carcinoma using nuclear magnetic resonance-based serum metabolomics and self-organizing maps.
Zheng H; Ji J; Zhao L; Chen M; Shi A; Pan L; Huang Y; Zhang H; Dong B; Gao H
Oncotarget; 2016 Sep; 7(37):59189-59198. PubMed ID: 27463020
[TBL] [Abstract][Full Text] [Related]
4. Plasma Glycosaminoglycans as Diagnostic and Prognostic Biomarkers in Surgically Treated Renal Cell Carcinoma.
Gatto F; Blum KA; Hosseini SS; Ghanaat M; Kashan M; Maccari F; Galeotti F; Hsieh JJ; Volpi N; Hakimi AA; Nielsen J
Eur Urol Oncol; 2018 Oct; 1(5):364-377. PubMed ID: 31158075
[TBL] [Abstract][Full Text] [Related]
5. UPLC-MS based urine untargeted metabolomic analyses to differentiate bladder cancer from renal cell carcinoma.
Wang Z; Liu X; Liu X; Sun H; Guo Z; Zheng G; Zhang Y; Sun W
BMC Cancer; 2019 Dec; 19(1):1195. PubMed ID: 31805976
[TBL] [Abstract][Full Text] [Related]
6. mTOR and mTOR phosphorylation status in primary and metastatic renal cell carcinoma tissue: differential expression and clinical relevance.
Rausch S; Schollenberger D; Hennenlotter J; Stühler V; Kruck S; Stenzl A; Bedke J
J Cancer Res Clin Oncol; 2019 Jan; 145(1):153-163. PubMed ID: 30368665
[TBL] [Abstract][Full Text] [Related]
7. L-DOPA decarboxylase mRNA levels provide high diagnostic accuracy and discrimination between clear cell and non-clear cell subtypes in renal cell carcinoma.
Papadopoulos EI; Petraki C; Gregorakis A; Chra E; Fragoulis EG; Scorilas A
Clin Biochem; 2015 Jun; 48(9):590-5. PubMed ID: 25721989
[TBL] [Abstract][Full Text] [Related]
8. iTRAQ-based quantitative proteomic analysis reveals potential early diagnostic markers of clear-cell Renal cell carcinoma.
Zhang L; Jiang H; Xu G; Chu N; Xu N; Wen H; Gu B; Liu J; Mao S; Na R; Jing Y; Ding Q; Zhang Y; Wang L
Biosci Trends; 2016 Jul; 10(3):210-9. PubMed ID: 27319973
[TBL] [Abstract][Full Text] [Related]
9. Role of metabolomics-derived biomarkers to identify renal cell carcinoma: a comprehensive perspective of the past ten years and advancements.
Gupta A; Nath K; Bansal N; Kumar M
Expert Rev Mol Diagn; 2020 Jan; 20(1):5-18. PubMed ID: 31825678
[No Abstract] [Full Text] [Related]
10. LC-MS based serum metabonomic analysis for renal cell carcinoma diagnosis, staging, and biomarker discovery.
Lin L; Huang Z; Gao Y; Yan X; Xing J; Hang W
J Proteome Res; 2011 Mar; 10(3):1396-405. PubMed ID: 21186845
[TBL] [Abstract][Full Text] [Related]
11. Metabolic Footprinting of a Clear Cell Renal Cell Carcinoma in Vitro Model for Human Kidney Cancer Detection.
Knott ME; Manzi M; Zabalegui N; Salazar MO; Puricelli LI; Monge ME
J Proteome Res; 2018 Nov; 17(11):3877-3888. PubMed ID: 30260228
[TBL] [Abstract][Full Text] [Related]
12. Low NR3C2 levels correlate with aggressive features and poor prognosis in non-distant metastatic clear-cell renal cell carcinoma.
Zhao Z; Zhang M; Duan X; Deng T; Qiu H; Zeng G
J Cell Physiol; 2018 Oct; 233(10):6825-6838. PubMed ID: 29693713
[TBL] [Abstract][Full Text] [Related]
13. miR-144-3p as a novel plasma diagnostic biomarker for clear cell renal cell carcinoma.
Lou N; Ruan AM; Qiu B; Bao L; Xu YC; Zhao Y; Sun RL; Zhang ST; Xu GH; Ruan HL; Yuan CF; Han WW; Shi HC; Yang HM; Zhang XP
Urol Oncol; 2017 Jan; 35(1):36.e7-36.e14. PubMed ID: 27633984
[TBL] [Abstract][Full Text] [Related]
14. Prognostic implications of the immunohistochemical expression of human kallikreins 5, 6, 10 and 11 in renal cell carcinoma.
Petraki CD; Gregorakis AK; Vaslamatzis MM; Papanastasiou PA; Yousef GM; Levesque MA; Diamandis EP
Tumour Biol; 2006; 27(1):1-7. PubMed ID: 16340244
[TBL] [Abstract][Full Text] [Related]
15. LC-MS based metabolomic profiling for renal cell carcinoma histologic subtypes.
Jing L; Guigonis JM; Borchiellini D; Durand M; Pourcher T; Ambrosetti D
Sci Rep; 2019 Oct; 9(1):15635. PubMed ID: 31666664
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of extensive necrosis in renal cell carcinoma.
Collins J; Epstein JI
Hum Pathol; 2017 Aug; 66():108-114. PubMed ID: 28669641
[TBL] [Abstract][Full Text] [Related]
17. MicroRNA-15a expression measured in urine samples as a potential biomarker of renal cell carcinoma.
Mytsyk Y; Dosenko V; Borys Y; Kucher A; Gazdikova K; Busselberg D; Caprnda M; Kruzliak P; Farooqi AA; Lubov M
Int Urol Nephrol; 2018 May; 50(5):851-859. PubMed ID: 29549624
[TBL] [Abstract][Full Text] [Related]
18. Stem cell markers aldehyde dehydrogenase type 1 and nestin expressions in renal cell cancer.
Ozbek E; Calik G; Otunctemur A; Aliskan T; Cakir S; Dursun M; Somay A
Arch Ital Urol Androl; 2012 Mar; 84(1):7-11. PubMed ID: 22649953
[TBL] [Abstract][Full Text] [Related]
19. Biomarkers of epithelial-mesenchymal transition in localized, surgically treated clear-cell renal cell carcinoma.
Gasinska A; Jaszczynski J; Adamczyk A; Janecka-Widła A; Wilk W; Cichocka A; Stelmach A
Folia Histochem Cytobiol; 2018; 56(4):195-206. PubMed ID: 30569446
[TBL] [Abstract][Full Text] [Related]
20. A pilot investigation of a urinary metabolic biomarker discovery in renal cell carcinoma.
Zhang M; Liu X; Liu X; Li H; Sun W; Zhang Y
Int Urol Nephrol; 2020 Mar; 52(3):437-446. PubMed ID: 31732842
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]